Quantcast

Latest AFPep Stories

2012-04-02 15:31:10

At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells. Over time, however, the disease often becomes resistant to estrogen deprivation from the drugs–making...

2011-11-14 15:16:23

UCSF researchers discuss possible multi-drug strategy for breast cancer at news conference In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and...

2011-11-14 11:35:29

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer. They also found that introducing a novel histone deacetylase inhibitor in hormone therapy treatment can overcome resistance to hormonal therapy. "We always thought that resistance was primarily an inborn or genetic effect," said Pamela N. Munster, M.D., director of the Early-Phase Clinical...

2011-07-25 07:00:00

EMERYVILLE, Calif., July 25, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today the successful completion of 13 weeks repeat dose animal toxicology studies with Menerba. "Prior to Phase 3 initiation we were required by FDA to complete two 13 weeks repeat dose animal toxicology studies," commented Dr. Isaac Cohen, chairman and chief executive...

2011-03-31 01:34:12

The estrogen inhibitor tamoxifen can prevent breast cancer from coming back in treated women whose tumors grow in the presence of the hormone. Unfortunately, tamoxifen's anti-tumor effect wanes in about half of these women, and now researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine think they know why. Low levels or loss of the protein Rho guanine disassociation inhibitor alpha or Rho GDI alpha can cause tumors to resist the effects of treatment with...

2010-04-01 08:49:18

Professor Didier Picard's team in Switzerland uncovers a mechanism of resistance of tumor cells to the widespread treatment of the so-called hormone-dependent types Tumor cells depend upon estrogens to survive and proliferate in about 70% of all breast cancer cases. The most frequently used treatment to fight this variety of tumors relies on anti-estrogens such as tamoxifen. However, resistance to this type of therapy develops in more than 30% of the patients. Understanding the mechanisms...

2009-11-24 17:38:53

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein (AFP), may serve as a viable, well-tolerated agent for the treatment and prevention of breast cancer, according to findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research. "Hormones in pregnancy, such as estrogen, all induce AFP, which directly inhibits the growth of breast...

2009-10-20 07:00:00

EMERYVILLE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the publication of results from its study on the inhibitory effect of tamoxifen on estrogen receptor beta (ERb) gene regulation. The results of the study, which will be published in Molecular and Cellular Endocrinology, demonstrate that tamoxifen inhibits the beneficial effects of ERb in the prevention of breast cancer cell proliferation. "Tamoxifen has been successfully used to treat...

2009-06-24 07:56:03

Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.Sherene Loi, from the Peter MacCallum Cancer Centre, Melbourne, worked with a team of Australian and Belgian researchers to investigate the differences between those estrogen receptor positive (ER+)...

2009-06-11 12:25:40

Dutch and U.S. medical researchers have discovered a protein profile that may predict whether a breast cancer patient will be resistant to tamoxifen therapy. Tamoxifen is a widely used and effective drug designed to treat breast cancer. But the scientists said resistance to tamoxifen is problematic in recurrent disease that affects 25 percent to 35 percent of patients because therapy resistant metastatic tumor cells are a major cause of death. In the new study, Arzu Umar of the Erasmus...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.